No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517C72500
- 0.45
- 0.000.00%
15min DelayClose May 8 16:00 ET
0.50High0.30Low
0.35Open0.45Pre Close59 Volume225 Open Interest72.50Strike Price2.61KTurnover97.07%IV22.69%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier9DDays to Expiry0.45Time Value100Contract SizeAmericanOptions Type0.1140Delta0.0211Gamma125.22Leverage Ratio-0.0955Theta0.0016Rho14.28Eff Leverage0.0181Vega
Intraday
- 5D
- 1D
News
Exact Sciences Stock Plunges On Q1 Earnings: What You Need To Know
Exact Sciences Corp (NASDAQ:EXAS) shares are trading lower in Wednesday's after-hours session on the heels of the company's first-quarter results. Here's a rundown of the report.What Happened: Exact S
Buy Rating Affirmed for Exact Sciences Amidst Strong Growth and Innovative Pipeline
Earnings Call Summary | Exact Sciences(EXAS.US) Q1 2024 Earnings Conference
The following is a summary of the Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript:Financial Performance:Exact Sciences reported a 6% revenue increase in Q1 to $638 million.The GAAP
Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript
Exact Sciences Corporation (EXAS) Q1 2024 Earnings Call Transcript
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Exact Sciences Down 17% on Quarterly Bottom Line Miss, Maintaining 2024 Guidance
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more